Eli Lilly and Co expects to submit a market application for orforglipron for weight management to Global regulatory authorities by the end of the year.

On April 17, Eli Lilly and Co announced positive top-line results from the phase 3 clinical study ACHIEVE-1, which evaluated the safety and efficacy of orforglipron compared to placebo in patients with type 2 diabetes whose blood sugar control remained inadequate despite diet control and exercise. Eli Lilly and Co stated that Orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist to successfully complete phase 3 trials without restrictions on diet or drinking. Eli Lilly and Co expects to submit a market application for orforglipron for weight management to Global regulatory authorities by the end of this year and plans to submit its application for treating type 2 diabetes in 2026.